Mucosal Associated Invariant T Cell During Viral Pneumonia and Acute Respiratory Distress Syndrome

Launched by UNIVERSITY HOSPITAL, TOURS · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of a specific type of immune cell called Mucosal Associated Invariant T (MAIT) cells during severe viral pneumonia, which can lead to a serious condition called Acute Respiratory Distress Syndrome (ARDS). ARDS is a severe breathing problem that can occur after infections like COVID-19 or the flu, and it can be life-threatening. The researchers want to learn more about how MAIT cells respond in patients with ARDS caused by viral infections, as understanding this could help identify new ways to treat these patients.

For this study, they are looking for adult patients who are at least 18 years old and are admitted to the Intensive Care Unit (ICU) for serious respiratory issues, such as pneumonia or severe injuries. Participants will have their immune responses closely monitored over time to gather important information. It’s important to note that patients with certain conditions, like severe immune system problems or those undergoing specific cancer treatments, won’t be able to participate. The goal of the trial is to better understand these immune responses and potentially find targeted therapies that could improve the care of patients suffering from ARDS related to viral infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Patients admitted to critical care (Intensive Care Unit, Continuous Monitoring Unit, Intensive Care Unit) at the CHRU de Tours
• * Patients admitted to critical care for one of the following reasons:
• • Acute community-acquired pulmonary infection (pneumonia),
• • Severe acute pancreatitis, with onset of ARDS criteria less than 48 hours ago,
• • Severe isolated head injury requiring invasive mechanical ventilation,
• • Severe burn defined by a burned surface area exceeding 20% and/or deep lesions exceeding 3% of the total body surface area, with the onset of ARDS criteria less than 48 hours ago,
• • Patient admitted to Intensive Care Medicine, requiring invasive mechanical ventilation,
• • Patient admitted to cardiac surgery for scheduled surgery for valve replacement and/or coronary artery bypass grafting, with inclusion the day before surgery,
• Non-inclusion criteria :
• • Patients with severe immunosuppression (impairing the ability to analyse the immune response, particularly T lymphocytes): active haematological malignancy, solid organ transplantation or bone marrow transplantation, systemic immunosuppressive treatment, ongoing chemotherapy (including immune checkpoint inhibitors).
• • Person who has objected to data processing
• • Patient under guardianship or curatorship